Carfilzomib can lead to cardiovascular toxicity in multiple myeloma patients

(University of Pennsylvania School of Medicine) The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows the therapy comes with the risk of cardiovascular problems in a higher than expected percentage of patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

ConclusionsDAC treatment can inhibit myeloma cell proliferation and induce enhanced autologous T cell immune response by depleting M-MDSCs in the MM microenvironment. We believe that DAC treatment could improve the prognosis of MM in future.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Conclusiones: El tratamiento de la OMAM depende del estadio de la enfermedad; la mandibulectomía es un tratamiento efectivo en el estadio 3 y la secuestrectomía en el estadio 2; el estadio 1 suele controlarse con tratamiento conservador.ABSTRACT Introduction: Bisphosphonates are a family of drugs used to inhibit bone resorption. One of their secondary effects is osteonecrosis of the jaws (ONJ). In 2010, scientists began to publish cases of osteonecrosis of the jaws associated with a new drug, denosumab. In 2014 it was recommended to change the name of ONJ to medication-related osteonecrosis of the jaws (MONJ)...
Source: Revista Espanola de Cirugia Oral y Maxilofacial - Category: ENT & OMF Source Type: research
Authors: Tang H, Xu L, Liang X, Gao G Abstract Multiple myeloma (MM) is a hematological malignancy that lacks a cure. However, novel combination therapy is a current anti-MM strategy. Doxorubicin (DOX) is a type of anthracycline which is a first-line chemotherapeutic for treating MM and induces senescence in many types of cancer. Dinaciclib is a potent, small molecule CDK inhibitor with promise for treating several types of cancer in I/II phase clinical trials. In the present study the anticancer effects and underlying mechanisms of dinaciclib combined with DOX in MM RPMI-8226 cells were investigated. Results indic...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Zhang Z, Li Z, Chen W Abstract G protein-coupled receptor kinase 6 (GRK6) is highly expressed in multiple myeloma (MM) cell lines, but absent or only weakly expressed in most primary human somatic cells. In the present study, GRK6 expression was assessed in MM patients and healthy individuals by quantitative polymerase chain reaction. Flow cytometry were performed to measure the apoptosis of lentivial-transfected MM1R cells. Western blot analysis was performed to assess the apoptosis and signal transducer and activator of transcription 3 pathway-related factors. The results demonstrated that GRK6 was diffe...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting, Published online: 09 November 2018; doi:10.1038/s41408-018-0141-0Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts, Published online: 08 November 2018; doi:10.1038/s41408-018-0139-7Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma, Published online: 08 November 2018; doi:10.1038/s41408-018-0147-7Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma, Published online: 08 November 2018; doi:10.1038/s41408-018-0144-xEvolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
(Natural News) Cinnamon does more than add a pleasant and appetizing aroma to your favorite dishes – it can also help treat certain cancers. A study published in the Journal of Herbal Medicine found that cinnamon has the ability to modify the growth of and kill blood cancer cells. Myeloma is a type of blood...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study, Published online: 07 November 2018; doi:10.1038/s41408-018-0135-yLonger procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prosp...
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Heart | Myeloma | Toxicology | University of Pennsylvania